Bexorg, Biohaven Announce Multi-Program CNS Therapy Collaboration

Bexorg, a techbio company specializing in brain research, has partnered with Biohaven to advance treatments for central nervous system disorders using Bexorg’s novel whole-brain discovery platform. This technology uniquely allows the perfusion of isolated human and pig brains with artificial blood to restore metabolic activity, enabling detailed molecular analysis and mechanistic insights that support Biohaven’s preclinical drug development programs. The collaboration focuses on validating target engagement, generating biomarkers, and analyzing pharmacokinetic and pharmacodynamic relationships to enhance CNS drug discovery and identify responsive patient subgroups. Biohaven currently holds an "Outperform" brokerage rating with significant upside potential according to analysts. Separately, the Lieber Institute for Brain Development is expanding its research capabilities by migrating to Amazon Web Services to leverage generative AI for developing new treatments for brain disorders, including schizophrenia, through a new AI tool called GRAPE. This move underscores the growing integration of AI and cloud computing in advancing neuroscience and drug discovery.